Indian drug maker Ranbaxy is moving swiftly to capitalize on Russian policies to encourage establishing a local production presence, signing a memorandum of understanding with Russia's Yaroslavl regional authority to help the province build a medical and pharmaceutical center. The "going local, going to regions" move could set a model for international pharma companies eying the Russian market, says a Russia biologics expert
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
